Tuesday, 08 December 2015 04:35 PM
HOUSTON, TX / ACCESSWIRE / December 8, 2015 / Biotechnology stocks have had another huge year in the OTC markets.
Generally, biotechnology stocks make some of the largest moves on the OTC. The reason being most of the biggest rags to riches stories on the OTC are biotech companies.
Why is that? Most biotechs have long expensive trial phases to get through before they'll ever make a dime of revenue, and going public helps these companies raise the capital necessary to make it to solvency. But, if they do make it through the trial phases the payoff can be huge.
Why do speculative investors love biotechs? Biotechnology companies generally have a novel technology or concept to solve a multi billion dollar problem, and earn patents throughout the trial phases.
This is why we have been looking at Global Arena Holding, Inc. (OTC: GAHC).
GAHC is not a biotechnology stock, but it shares many of the same properties that make it a company you should look at immediately.
Global Arena has invested in Blockchain Technologies Corporation. ("BTC"), and is working toward a full acquisition. BTC leverages the groundbreaking blockchain, which some - like Marc Andreessen - are calling the most significant technology since the internet, and creates patents for novel uses of the blockchain that will solve multi billion dollar inefficiencies across a number of industries. These include financial markets, banking, electronic payment systems, private & public contracts and election services through various applications such as: exchanges, smart contracts and voting.
Much like a biotech:
- Novel Technology
- Solving Multi Billion Dollar Problems
- Creating Patents
Unlike biotechs, GAHC, is already generating revenues through its election services subsidiary, Global Election Services.
To bring it all full circle, GAHC's BTC will potentially be using its Blockchain Apparatus to make filing patents easier and more efficient, which as mentioned earlier, is a big part of the biotechnology business.
Blockchain technology, which many know as the backbone of the digital currency Bitcoin, is essentially a uncompromisable public ledger of transactions. All transactions are broadcast to a network of subscribing nodes, and each node updates its own copy of the ledger with the new transactions. Once a new group of transactions is verified, a block is created and added to the blockchain. All transactions for the ledger are publicly visible and verifiable based on previous blocks. Essentially, blockchain is a ledger that anyone can add things to but no one can remove anything from. This creates a certain and verifiable record on an electronic system that cannot be hacked.
GAHC looks to be one of the first companies to fully leverage and benefit from this technology.
This could create movements similar, to several biotechnology companies we've been paying attention to:
KaleBios Pharmaceuticals (NASDAQ: KBIO) has had a huge past few weeks since being taken over by CEO Martin Shkreli, who has spearheaded a 9,830% move. That's no misprint, it shows the kind of movement these high potential stocks can make.
Endonovo Therapeutics, Inc. (OTC: ENDV) has made an 890% move just this week! ENDV is developing two bioelectronic-based platforms for regenerative medicine. Immunotronic(TM), a non-invasive and non-implantable immuno-regulatory device designed to treat inflammatory conditions in vital organs, including acute organ failure; and Cytotronics(TM), a proprietary bioelectronic-based method of creating stem cells with enhanced biological and therapeutic properties.
In a Schedule 13G filing, Steve Cohen's Point72 Asset Management reported owning 1.41 million shares of Cara Therapeutics Inc. (NASDAQ: CARA), which accounted for 5.2% of the company's outstanding shares. Cohen's family office owned a mere 24,800 shares of the company as of September 30. The clinical-stage biopharmaceutical company focuses on the development of new chemical products that target the body's peripheral nervous system in order to relieve pain and pruritus. Shares of Cara Therapeutics Inc. (NASDAQ: CARA) had advanced by more than 100% through the end of September, when the sell-off in biotechnology stocks kicked off. Nevertheless, the stock is still 38% in the green year-to-date, and will most likely continue to be guided by investors' expectations for the success of its product candidates in the upcoming quarters.
Biotechnology stocks can make massive moves, Global Arena Holding, Inc. (GAHC) shares several properties which give it the same kind of explosive potential these speculative biotechs have and is already generating revenues with significant increases expected to continue. Make sure to take a close look at GAHC.
For more information about the blockchain, click here:
http://globalarenaholding.com/blockchain-news/the-beginners-guide-to-blockchain/
Legal Disclaimer/Disclosure: This is a sponsored article. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. For The Full Disclaimer, click here http://capitalgainsreport.com/disclaimer/.
SOURCE: Capital Gains Report